Sean E. Harper
Managing Partner @ Westlake Village BioPartners
Los Angeles, United States
Sean E. Harper is a Series A investor at Westlake Village BioPartners in Los Angeles focused on Medical and Health Care. Dr. Harper joined Amgen in 2002 as vice president, Development, and has held several leadership roles, including heading the establishment of Amgen's Medical Sciences capability, a translational medicine group focused on biomarker discovery, development, and integration into early phase clinical studies. Dr. Harper served as vice president ofGlobal Regulatory Affairs and Safety before assuming the role of senior vice president of Global Development and Corporate Chief Medical Officer. He became executive vice president, Research and Development in February 2012.Prior to joining Amgen, Dr. Harper was senior director of clinical genomics at Merck Research Laboratories. He attended medical school at the University of California at San Francisco, completed internal medicine and gastroenterology training at the Massachusetts General Hospital, and was a postdoctoral fellow in the laboratory of Phillip A. Sharp at the Massachusetts Institute of Technology.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Sean E. Harper invests in
Stages Sean E. Harper invests in
Countries Sean E. Harper invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (50%)
- Health Care 1 (50%)
- Life Science 1 (50%)
- Therapeutics 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Latigo Biotherapeutics
|
Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability. | $135M / Series A / Feb 14, 2024 | |
Dantari
|
Developer of a pharmaceutical platform and drugs created for the treatment of the central nervous system. The company's platform and therapies specialize in the research and development of small and large molecule therapeutics across the blood-brain barrier, enabling clients to have rapidly advance therapies to treat the patients and providemeaningful medical improvement in their lives. | $47M / Series A / Dec 08, 2022 |
Co-Investors
Westlake Village BioPartners is a venture capital firm focused on incubating and building life sciences companies with entrepreneurs that have the potential to bring transformative therapies and technologies to patients. The Westlake model is built on the founding team’s unique experience in successfully identifying and developing breakthroughtherapies and building organizations.
Westlake Village BioPartners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Sean E. Harper
Managing Partner
|
|||
Beth Seidenberg
Managing Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Sean E. Harper invest in?
Sean E. Harper invests primarily in Medical, Health Care and Life Science startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Sean E. Harper?
Public channels for Sean E. Harper include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Sean E. Harper last invest?
The most recent investment recorded for Sean E. Harper closed in Feb 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
